Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia : A multicenter study
Copyright © 2021 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved..
OBJECTIVES: Superimposed multi-drug resistant organisms (MDROs) co-infection can be associated with worse outcomes in patients with severe coronavirus disease 2019 (COVID-19), even if these patients were managed with strict airborne and contact precautions. Identifying risk factors for isolation of MDROs is critical to COVID-19 treatment.
METHODS: All eligible adult patients with confirmed COVID-19 pneumonia from 10 hospitals in the Republic of Korea between February 2020 and May 2020 were retrospectively enrolled. Using this cohort, epidemiology and risk factors for isolation of MDROs were evaluated.
RESULTS: Of 152 patients, 47 with microbial culture results were included. Twenty isolates of MDROs from 13 (28%) patients were cultured. Stenotrophomonas maltophilia (5 isolates) was the most common MDRO, followed by methicillin-resistant staphylococcus aureus (4 isolates). MDROs were mostly isolated from sputum samples (80%, 16/20). The median time from hospitalization to MDRO isolation was 28 days (interquartile range, 18-38 days). In-hospital mortality was higher in patients with MDRO isolation (62% vs 15%; P = .001). Use of systemic corticosteroids after diagnosis of COVID-19 (adjusted odds ratio [aOR]: 15.07; 95% confidence interval [CI]: 2.34-97.01; P = .004) and long-term care facility (LTCF) stay before diagnosis of COVID-19 (aOR: 6.09; 95% CI: 1.02-36.49; P = .048) were associated with MDRO isolation.
CONCLUSIONS: MDROs were isolated from 28% of COVID-19 pneumonia patients with culture data and 8.6% of the entire cohort. Previous LTCF stay and adjunctive corticosteroid use were risk factors for the isolation of MDROs. Strict infection prevention strategies may be needed in these COVID-19 patients with risk factors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
American journal of infection control - 49(2021), 10 vom: 10. Okt., Seite 1256-1261 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Son, Hyo-Ju [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimicrobial resistance |
|---|
| Anmerkungen: |
Date Completed 29.09.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ajic.2021.06.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326940944 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326940944 | ||
| 003 | DE-627 | ||
| 005 | 20231225195657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajic.2021.06.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1089.xml |
| 035 | |a (DE-627)NLM326940944 | ||
| 035 | |a (NLM)34146624 | ||
| 035 | |a (PII)S0196-6553(21)00403-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Son, Hyo-Ju |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia |b A multicenter study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: Superimposed multi-drug resistant organisms (MDROs) co-infection can be associated with worse outcomes in patients with severe coronavirus disease 2019 (COVID-19), even if these patients were managed with strict airborne and contact precautions. Identifying risk factors for isolation of MDROs is critical to COVID-19 treatment | ||
| 520 | |a METHODS: All eligible adult patients with confirmed COVID-19 pneumonia from 10 hospitals in the Republic of Korea between February 2020 and May 2020 were retrospectively enrolled. Using this cohort, epidemiology and risk factors for isolation of MDROs were evaluated | ||
| 520 | |a RESULTS: Of 152 patients, 47 with microbial culture results were included. Twenty isolates of MDROs from 13 (28%) patients were cultured. Stenotrophomonas maltophilia (5 isolates) was the most common MDRO, followed by methicillin-resistant staphylococcus aureus (4 isolates). MDROs were mostly isolated from sputum samples (80%, 16/20). The median time from hospitalization to MDRO isolation was 28 days (interquartile range, 18-38 days). In-hospital mortality was higher in patients with MDRO isolation (62% vs 15%; P = .001). Use of systemic corticosteroids after diagnosis of COVID-19 (adjusted odds ratio [aOR]: 15.07; 95% confidence interval [CI]: 2.34-97.01; P = .004) and long-term care facility (LTCF) stay before diagnosis of COVID-19 (aOR: 6.09; 95% CI: 1.02-36.49; P = .048) were associated with MDRO isolation | ||
| 520 | |a CONCLUSIONS: MDROs were isolated from 28% of COVID-19 pneumonia patients with culture data and 8.6% of the entire cohort. Previous LTCF stay and adjunctive corticosteroid use were risk factors for the isolation of MDROs. Strict infection prevention strategies may be needed in these COVID-19 patients with risk factors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Long-term care facility | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Kim, Tark |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Eunjung |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Se Yoon |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Shinae |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Hyo-Lim |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min-Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Sun In |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Seongman |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min Jae |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sung-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Yun, Ji Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Jo, Kyeong Min |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yu-Mi |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seungjae |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jung Wan |e verfasserin |4 aut | |
| 700 | 1 | |a Jeon, Min Hyok |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Tae Hyong |e verfasserin |4 aut | |
| 700 | 1 | |a Choo, Eun Ju |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of infection control |d 1980 |g 49(2021), 10 vom: 10. Okt., Seite 1256-1261 |w (DE-627)NLM012639850 |x 1527-3296 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2021 |g number:10 |g day:10 |g month:10 |g pages:1256-1261 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajic.2021.06.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2021 |e 10 |b 10 |c 10 |h 1256-1261 | ||